Abingworth strengthens investment team with new appointments in the USA and the UK
"At the start of the year," said Abingworth, a leading international life sciences investment group, today announced three new appointments to its investment team in the UK and the US. Moreover, the founders of the firm have joined and Diya Malhotra has joined as a strategic manager. Jay will be based at the firm's Menlo Park, CA office and Lucille and Diya will work in London. They will work with the Partners across all locations, sourcing and evaluating new opportunities, and supporting existing venture investment.
Jay was a director of AbbVie Ventures, where he helped make equity investments in emerging biotech companies and served as spokesman for many companies within AbvVita's portfolio. Jay worked as a business strategy consultant focused on life sciences at ZS Associates and Campbell Alliance. Jay earned his MBA and PhD from the University of Chicago, and a BSc in Chemistry from Peking University.
Lucille joins Abingworth from F-Prime Capital where she worked as a Senior Associate focusing primarily on the early stage, novel therapeutic biotech companies. She worked at McKinsey & Co. Before that, she was in private equity, in European Pharmaceuticals and Medical Products practices. Lucille completed her clinical foundation and core medical training in the UK at the National Hospital for Neurology and Neurosurgery, UCLH, Imperial College and Barts Foundation NHS Trusts. Lucille holds a bachelor's degree in Clinical Neuroscience and an MBChB from the University of Glasgow.
Diya joins L.E.K. Consulting where she worked as a Consultant in its Life Sciences practice advising pharmaceutical and early to late-stage biotech clients on dozens of projects, including corporate strategy, and clinical and Diya holds a doctorate in clinical neuropharmacology from the Imperial College of London and he has BSc in Pharmacy from University College London.
"We're very happy to welcome Lucille, Jay and Diya to the team." According to the Managing Partner, Bali Muralidhar is a spokesman. Together they bring a wide range of experience in life sciences and strategic consulting, as well as strong scientific and clinical backgrounds. They will be great additions to Abingworth's transatlantic investment team, expanding our capacity to evaluate and invest in exciting early- and development-stage biotech companies and clinical co-development opportunities following the recent closing of our new funds
ABV 8 Abingworth Bioventures 8; ACCD2 - Abidingworth Clinical Co-Development Fund 2.
About Abingworth, About Yumba
Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps scientists to turn cutting-edge technology into novel medicines. By providing capital and expertise to top-class management teams building world-renowned companies. Since 1973, Abingworth invested in more than 175 life science companies since 1973 resulting in 45 M&As and 71 IPOs. Our therapeutic focused investments fall into three categories: seed and early stage, development stage and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals in London, Menlo Park and Boston offices.
Bali MuralidharManaging PartnerTel: +44 (0)20 7534 1500.
Media inquiries: Mark Swallow or David Dible, MEDiSTRAVA ConsultingTel: +44 (0)20 7638 9571Email: [email protected]
SOURCE Abingworth SOUTH.